BCI Suppresses RANKL-Mediated Osteoclastogenesis and Alleviates Ovariectomy-Induced Bone Loss

• Published in: Frontiers in pharmacology 2021-11, Vol.12, p.772540-772540
• Main Authors: Cai, Chenhui, Hu, Wenhui, Zhang, Ying, Hu, Xu, Yang, Sizhen, Qiu, Hao, Wang, Rujie, Ma, Min, Qiu, Yiyun, Chu, Tongwei
• Format: Article
• Language: English
• Subjects: BCI; bioinformatics; bone resorption; osteoclast; Pharmacology; postmenopausal osteoporosis
• ISSN: 1663-9812; 1663-9812
• DOI: 10.3389/fphar.2021.772540

Osteoporosis is a common aging-related metabolic disease that mainly occurs in older adults and postmenopausal women. Despite advances in anti-osteoporosis treatment, outcomes remain unsatisfactory due to detrimental side effects. BCI hydrochloride (BCI), a selective dual-specificity phosphatase 6 (DUSP6) inhibitor, is associated with multiple cellular functions, including inhibiting tumor growth and macrophage inflammation; however, its role in regulating osteoclast differentiation remains unknown. Here, we revealed that treatment with BCI attenuated RANKL-mediated osteoclast differentiation in vitro and alleviated ovariectomy-induced osteoporosis without obvious toxicity. Specifically, BCI disrupted F-actin ring formation and bone-resorption activity and decreased osteoclast-specific gene and protein levels in a dose-dependent manner. KEGG pathway analysis, GSEA based on transcriptome sequencing, and western blot results suggested that BCI inhibited RANKL-induced osteoclastogenesis by restraining STAT3 and NF-κB signaling and attenuating NF-κB/p65 interaction with NFATc1. These results revealed that BCI treatment prevented postmenopausal osteoporosis and might represent an effective approach for treating osteoporosis.